
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
ZMYM6 (zinc finger MYM-type containing 6) encodes a zinc finger protein predicted to possess DNA-binding activity and to participate in regulation of cellular organization. Available annotation associates ZMYM6 with cytoskeleton organization and regulation of cell morphogenesis, with predicted localization to the nucleus. These functions suggest a potential connection between nuclear regulatory activity and cellular structural processes.
Papillary thyroid carcinoma is represented by TPC-1, a human thyroid cancer cell line established from a thyroid tumor. The cells are classified as a human papillary thyroid carcinoma model and carry the characteristic RET/PTC1 rearrangement resulting from fusion of RET with CCDC6. TPC-1 is widely used for studies of thyroid cancer biology and RET-associated oncogenic signaling.
Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 4
Reference Transcript: NM_007167
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?